Objective Aortic dissection and aneurysms are the two most common life-threatening disorders affecting the aorta. Unless they are treated immediately, they result in shock and death in 80% of cases. However, according to Prof. Koskas, today up to 50% of patients with a high surgical risk cannot be treated with traditional open surgery. This implies that new and less invasive interventions are urgently needed. This is not only a European challenge, but a global one that impacts patients worldwide.Endonov is developing a disruptive solution called the CUSTOMI® Arch Branched stent system to overcome these existing problems. New woven fabric materials and advanced manufacturing procedures are playing a crucial role in CUSTOMI®’s unique design and fabrication. For the first time, smaller, tailor-made and multi-branched stent-grafts will be able to take the shape of the complex aortic arch anatomy of each patient. This medical device will be implanted and positioned with greater precision using an advanced sensor guided delivery system. This will allow to treat much more patients with different arch anatomies and ensure a longer term durability of the device.Endovascular surgeons from the famous US Mayo Clinic have stated CUSTOMI® Arch is currently the only solution in development able to overcome the major problem of complex aortic arch morphology and anatomy.Endovascular repair technology for the aortic arch is a highly growing and emerging field. Endonov has a huge opportunity to market a new medical device that will benefit thousands of patients all over the world, effectively lowering lethal rates of aortic arch pathologies.The commercialization of the CUSTOMI® Arch will make Endonov the first European company and a worldwide leader in the field of endovascular aortic repair with an estimated turnover of about 67 million euros and the creation of 71 new high-level jobs in Europe by 2022. Fields of science medical and health sciencesbasic medicineanatomy and morphologymedical and health sciencesclinical medicineangiologyvascular diseasesmedical and health sciencesclinical medicinesurgeryengineering and technologymaterials engineeringtextilesmedical and health sciencesbasic medicinepathology Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator ENDONOV Net EU contribution € 50 000,00 Address 19-21 RUE THALES DE MILET EMERGENCE TECHNOPOLE ET INCUBATEUR 72000 LE MANS France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Pays de la Loire Pays de la Loire Sarthe Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
